2-(二苯基氨基)乙酸 | 60085-74-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(二苯基氨基)乙酸
• 英文名称: N,N-diphenylglycine
• 英文别名: 2-(diphenylamino)acetic acid；diphenylglycine；N,N-diphenyl-glycine；N,N-Diphenyl-glycin；Diphenylaminoessigsaeure；diphenylamino acetic acid；(Diphenylamino)acetic acid；2-(N-phenylanilino)acetic acid
• CAS: 60085-74-7
• 化学式: C₁₄H₁₃NO₂
• 分子量: 227.263
• InChiKey: KFLKTDAONDZLAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2-(二苯基氨基)乙酸 在 氯化亚砜 作用下， 以 丙酮 、 苯 为溶剂， 反应 8.0h， 以88%的产率得到2-(N-phenylanilino)acetyl chloride
  参考文献：
  名称：

  Halwe, Kirti; Srivastava, S. K., Journal of the Indian Chemical Society, 1995, vol. 72, # 1, p. 59 - 62

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(二苯基亚甲基)甘氨酸乙酯 在 氢氧化钾 作用下， 生成 2-(二苯基氨基)乙酸
  参考文献：
  名称：

  Stolle, Journal fuer Praktische Chemie (Leipzig), 1914, vol. <2>90, p. 274

  摘要：

  DOI：

文献信息

• N-type calcium channel blockers
  申请人：Pajouhesh Hassan

  公开号：US20050165065A1

  公开（公告）日：2005-07-28

  The invention relates to novel 3-amino pyrrolidine derivatives, as well as methods for modulating calcium channel activity and for treating conditions associated with calcium channel function. In particular, the compounds generally contain at least one benzhydril moiety, and are useful in treating conditions which benefit from blocking calcium ion channels.

  这项发明涉及新型3-氨基吡咯烷衍生物，以及调节钙通道活性和治疗与钙通道功能相关疾病的方法。具体来说，这些化合物通常至少含有一个苯基甲酰基团，可用于治疗受益于阻断钙离子通道的疾病。
• [EN] ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF<br/>[FR] DÉRIVÉS AMINOESTÉRIFIÉS D'ALCALOÏDES ET COMPOSITION MÉDICINALE LES INCLUANT
  申请人：CHIESI FARMA SPA

  公开号：WO2010072338A1

  公开（公告）日：2010-07-01

  The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, to methods of preparing such derivatives, to compositions comprising them and therapeutic use thereof.

  本发明涉及作为毒蕈碱受体拮抗剂的生物碱氨基酸酯衍生物，制备此类衍生物的方法，包含它们的组合物以及它们的治疗用途。
• Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
  申请人：——

  公开号：US20020065391A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of the formula I 1 which are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention also relates to processes for their preparation, to the use of compounds of the formula I for the treatment or prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and also to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases, and to pharmaceutical preparations which contain the compounds of the formula I.

  本发明涉及式I的化合物，该化合物是白细胞粘附和迁移的抑制剂和/或属于整合素群的粘附受体VLA-4的拮抗剂。该发明还涉及它们的制备方法，化合物式I用于治疗或预防由于白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或基于VLA-4受体与其配体相互作用而发挥作用的细胞-细胞或细胞-基质相互作用的疾病，例如炎症过程、类风湿关节炎或过敏性疾病，以及化合物式I用于生产用于此类疾病的药物，以及含有化合物式I的药物制剂。
• 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220148A1

  公开（公告）日：2004-11-04

  Compounds of the formula I 1 in which B, D, E, R, W, Y, Z, b, c, d, e, f, g and h have the meanings indicated in the claims, are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention relates to the use of compounds of the formula I and of pharmaceutical preparations which contain such compounds for the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and it also relates to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases. It further relates to novel compounds of the formula I.

  公式I中B、D、E、R、W、Y、Z、b、c、d、e、f、g和h具有索引中指示的含义，是白细胞粘附和迁移的抑制剂和/或属于整合素群的粘附受体VLA-4的拮抗剂。本发明涉及公式I化合物的使用以及含有这种化合物的药物制剂，用于治疗和预防由白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用在其中起作用的炎症过程、类风湿关节炎或过敏性疾病等，还涉及公式I化合物用于生产用于治疗此类疾病的药物。此外，还涉及公式I的新化合物。
• Reagent-free continuous thermal tert-butyl ester deprotection
  作者：Kevin P. Cole、Sarah J. Ryan、Jennifer McClary Groh、Richard D. Miller

  DOI：10.1016/j.bmc.2017.03.020

  日期：2017.12

  enables the use of non-standard reaction conditions such as high temperatures and pressures while in the liquid phase. This expands the chemist's toolbox and can enable previously unthinkable chemistry to proceed with ease. For a series of amphoteric amino acid derivatives, we have demonstrated the ability to hydrolyze the tert-butyl ester functionality in protic solvent systems. Using a continuous plug

  连续处理可以在液相中使用非标准反应条件，例如高温和高压。这扩展了化学家的工具箱，可以使以前无法想象的化学轻松进行。对于一系列两性氨基酸衍生物，我们已经证明了能够在质子溶剂系统中水解叔丁基酯官能团的能力。在120-240°C和15-40min的反应时间下使用连续活塞流反应器，无需进行pH调节或其他试剂即可实现所需的转化。然后将该方法扩展到涵盖各种更具挑战性的底物，以测试选择性和外消旋潜力。